Search Results
Results found for "Omass Therapeutics"
- 📰 GPCR Weekly News, May 13 to 19, 2024
Mark your calendar for the GPCRs as Therapeutic Targets symposium on October 11th, 2024.
- Transmembrane domains of GPCR dimers – a novel hot spot for drug discovery
GPCR dimers are therefore emerging drug targets in different therapeutic areas including depression,
- 📰 GPCR Weekly News, December 18 to 31, 2023
Morgan Healthcare Conference Andrew Hopkins appointed CBE by HM King Charles III Voyager Therapeutics
- Illuminating GPCR Research: FRET and BRET-Based Sensors Shed Light on Cellular Signaling
continue to propel our quest to unravel the complexities of GPCR signaling and pave the way for novel therapeutic
- Using Live-cell High-Content Screening to Characterize CB2 Ligands: Insights From 16 Synthetic Cannabinoids
Despite its therapeutic potential, CB2 pharmacology remains difficult to interrogate with confidence.
- 📰 GPCR Weekly News, April 8 to 14, 2024
Industry News Monash University retains its N° 2 global ranking for Pharmacy and Pharmacology Addex Therapeutics
- 📰 GPCR Weekly News, February 19 to 25, 2024
GPCR Binders, Drugs, and more Advances in structure-based drug design: The potential for precision therapeutics
- 📰 GPCR Weekly News
GPCRs in Neuroscience CGRP physiology, pharmacology, and therapeutic targets: Migraine and beyond.
- A robust and Efficient FRET-Based Assay for Cannabinoid Receptor Ligands Discovery.
crystal structures of both CBRs.[4–8] A key challenge in CBR modulator development is separating the therapeutic New Insights and Potential Therapeutic Targeting of CB2 Cannabinoid Receptors in CNS Disorders.
- Fluorescence based HTS compatible ligand binding assays for dopamine D3 receptors in baculovirus preparations and live cells
have been approved as drugs, however they often have serious side effects and too low or temporary therapeutic Pharmacology & Therapeutics  2016 , 165 , 164–177. https://doi.org/10.1016/j.pharmthera.2016.06.007
- Unlocking Cell's Secrets: Spontaneous β-Arrestin-Membrane Preassociation Drives Receptor-Activation
Pharmacology & therapeutics, 89(2), 139–147. https://doi.org/10.1016/s0163-7258(00)00107-8
- Chemerin Forms: Their Generation and Activity
Methods of identifying and determining the levels of different chemerin forms in both mass and activity
- Label-free LC-MS based assay to characterize small molecule compound binding to cells
Here we developed and validated a label-free, liquid chromatography-mass spectrometry (LC-MS) based cell
- Design Pharmaceuticals Closes $5 Million Pre-series A Round to Accelerate Commercialization of ...
Ultrahigh Throughput Drug Discovery Platform "April 12, 2022 07:00 AM Eastern Daylight Time CAMBRIDGE, Mass
- Feeder or trigger – CCR2 as a scavenger and regulator of cell migration
This scavenging function should be considered when evaluating the safety and therapeutic efficacy of
- How GPCR Collaboration Built an Innovation Engine
Timing, leadership alignment, and a critical mass of motivated scientists converged.
- Structural landscape of the Chemokine Receptor system
binding and receptor activation will pave the way for significant advancements in the development of therapeutics
- Orthosteric Binding Experiments: How to Avoid the Most Common Data Pitfalls
Protein concentration: Â Too much receptor depletes tracer and invalidates mass-action assumptions.








